LUNESTA

LOE Approaching

eszopiclone

NDAORALTABLET
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.

Indications (1)

Clinical Trials (5)

NCT02455271N/ACompleted

Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

Started Oct 2012
438 enrolled
Insomnia
NCT02452684N/ACompleted

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients

Started Oct 2012
4,876 enrolled
Insomnia
NCT00770692Phase 3Completed

A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

Started Oct 2008
369 enrolled
Insomnia
NCT00770510Phase 2/3Completed

A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

Started Sep 2008
192 enrolled
Primary Insomnia
NCT00699608Phase 3Completed

An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

Started Jul 2008
91 enrolled
Healthy SubjectsSleep Initiation and Maintenance Disorders